Sugi Predict

Sugi Predict / Compounds / SCHEMBL291784

SCHEMBL291784

SCHEMBL291784

CCNC(=O)C(CC)(C(C)C)C(C)C

nearest known ligand 0.35

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ MMP1 P03956 1/20 0.33
▸ MMP2 P08253 1/20 0.33
▸ MMP3 P08254 1/20 0.33
▸ MMP9 P14780 1/20 0.33
▸ MMP8 P22894 1/20 0.33
▸ KMT2A Q03164 1/20 0.32
▸ CHRNB2 P17787 1/20 0.32
▸ CHRNB4 P30926 1/20 0.32
▸ CHRNA3 P32297 1/20 0.32
▸ CHRNA4 P43681 1/20 0.32
▸ MCL1 Q07820 1/20 0.31
▸ FAAH O00519 1/20 0.30
▸ SMN1; SMN2 Q16637 1/20 0.30
▸ CYP2D6 P10635 1/20 0.30
▸ CYP2C19 P33261 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27855150 0.90 — —
SCHEMBL2487164 0.86 — —
SCHEMBL31183070 0.83 MMP1 (0.38) MMP1MMP2MMP3MMP9KMT2A
SCHEMBL461620 0.80 CNR1 (0.31) —
SCHEMBL29171796 0.79 — —
SCHEMBL31183067 0.77 MEN1 (0.36) MMP1MMP2MMP9MMP8KMT2A
SCHEMBL11344853 0.77 MMP1 (0.33) MMP1MMP2MMP3MMP9MMP8
SCHEMBL31183069 0.76 CRBN (0.32) —
SCHEMBL3240918 0.74 MMP8 (0.34) MMP1MMP2MMP3MMP9MMP8
SCHEMBL18907822 0.74 MMP8 (0.34) MMP1MMP2MMP3MMP9MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 670 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260102365-A1 Topical method for treating inflammation of skin and nasal mucosa WEI EDWARD TAK (US) 2026-04-16 — — US claimed
US-20250352444-A1 Antimicrobial mixtures SYMRISE AG (DE) 2025-11-20 — — US claimed
US-20250228800-A1 Treatment of nasal cavity inflammation and mucus hypersecretion. WEI EDWARD T (US) 2025-07-17 — — US claimed
EP-4583718-A1 FLAVONOID COMPOSITIONS AND USES THEREOF Firmenich SA (CH) 2025-07-16 — — EP claimed
WO-2025132323-A1 COMPOSITIONS COMPRISING A SUNSCREEN ACTIVE AGENT DSM-FIRMENICH AG (CH) 2025-06-26 — — WO claimed
CN-120129464-A Flavonoid compound and application thereof 弗门尼舍有限公司 2025-06-10 — — CN claimed
US-20250163006-A1 New Coolants, and Preparations Containing Same SYMRISE AG (DE) 2025-05-22 — — US claimed
WO-2025068299-A1 AEROSOL-GENERATING ARTICLE, DEVICE AND SYSTEM JT INTERNATIONAL SA (CH) 2025-04-03 — — WO claimed
EP-4251122-B1 COMPOSITIONS THAT ENHANCE THE COOLING EFFECT FIRMENICH INCORPORATED (US) 2025-03-12 — — EP claimed
US-20250066320-A1 Active Ingredients with Sialagogue and Tingling/Fizzy Effect, and Preparations Containing Same SYMRISE AG (DE) 2025-02-27 — — US claimed
CN-102355825-A Compositions and methods for the treatment of throat discomfort CADBURY ADAMS USA LLC 2012-02-15 — — CN claimed
WO-2011163152-A1 ENHANCED RELEASE OF LIPOPHILIC INGREDIENTS FROM CHEWING GUM WITH HYDROCOLLOIDS KRAFT FOODS GLOBAL BRANDS LLC (US) 2011-12-29 — — WO claimed
EP-2375912-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF THROAT DISCOMFORT Kraft Foods Global Brands LLC (US) 2011-10-19 — — EP claimed
US-20110159141-A1 COOLING CONFECTIONERIES AND BEVERAGES INTERCONTINENTAL GREAT BRANDS LLC 2011-06-30 — — US claimed
WO-2010128026-A2 ORGANIC COMPOUNDS GIVAUDAN SA (CH) 2010-11-11 — — WO claimed
WO-2010096542-A2 CONFECTIONERIES PROVIDING MOUTH-MOISTENING REFRESHMENT CADBURY ADAMS USA LLC (US) 2010-08-26 — — WO claimed
WO-2010083133-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF THROAT DISCOMFORT CADBURY ADAMS USA LLC (US) 2010-07-22 — — WO claimed
CN-101522051-A Cooling confectioneries and beverages CADBURY ADAMS USA LLC (US) 2009-09-02 — — CN claimed
EP-2079321-A1 COOLING CONFECTIONERIES AND BEVERAGES Cadbury Adams USA LLC (US) 2009-07-22 — — EP claimed
WO-2008039522-A1 COOLING CONFECTIONERIES AND BEVERAGES CADBURY ADAMS USA LLC (US) 2008-04-03 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250352444-A1 Antimicrobial mixtures LRBA, MGLL, TAS2R50 MMP1 4580/4885MMP2 4234/4885MMP3 3527/4885
US-20250228800-A1 Treatment of nasal cavity inflammation and mucus hypersecretion. TRPM8, TAS2R8, TAS2R7 MMP1 1007/4885MMP2 1585/4885MMP3 1206/4885
US-20250066320-A1 Active Ingredients with Sialagogue and Tingling/Fizzy Effect, and Preparations Containing Same TAS2R5, TAS2R7, TAS2R8 MMP1 2923/4885MMP2 3966/4885MMP3 2925/4885
US-20260102365-A1 Topical method for treating inflammation of skin and nasal mucosa TAS2R8, TAS2R7, TRPM8 MMP1 1164/4885MMP2 2254/4885MMP3 1997/4885
US-20250163006-A1 New Coolants, and Preparations Containing Same TTR, TAS2R5, TAS2R50 MMP1 4393/4885MMP2 4728/4885MMP3 4663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.